As part of scientific exchange, Novartis is providing the most recent abstract(s) and/or presentation(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Before prescribing any product, always refer to the Prescribing Information (PI), Summary of Product Characteristics (SmPC), or product information as appropriate in your country. Information is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.
This is for your background and educational purposes only and may not be altered or further disseminated in any fashion.
For distribution in response to an unsolicited request for medical information subject to local approval.
Content to be used in accordance with local CPO guidelines
Adjuvant Ribociclib Plus Nonsteroidal Aromatase Inhibitor Therapy in Patients With HR+/HER2− Early Breast Cancer: NATALEE 5-Year Outcomes
John Crown, Daniil Stroyakovskiy, Denise A. Yardley, Chiun-Sheng Huang, Peter A. Fasching, Aditya Bardia, Stephen Chia, Seock-Ah Im, Miguel Martin, Binghe Xu, Carlos Barrios, Michael Untch, Rebecca Moroose, Sara Hurvitz, Gabriel N. Hortobagyi, Dennis Slamon, Frances Visco, Gonzalo Spera, Zheng Li, Sherene Loi
Proferred Paper/Oral Presentation #LBA14
Munich Auditorium - CityCube B | Friday, October 17, 2025 | 15:00-15:10 CEST (Proffered Paper/Oral Presentation) | 15:20-15:30 CEST (Discussion)
Risk of Recurrence (ROR) After Neoadjuvant Ribociclib Plus ET in Clinically High-Risk ER+/HER2− BC: First Interim Analysis of the SOLTI-RIBOLARIS Trial
Paul H. Cottu, Aleix Prat, Tomás Pascual, Huilin Hu, Estelle Roux, Francisco J.S. Bofill, Joana M. Ribeiro, Isabel Blancas, Thomas Bachelot, Jerôme Lemonnier, Juan M. Ferrero-Cafiero, Pablo Tolosa-Ortega, Antonio Mulero-Sánchez, Thayane A. Crestani, Roisin M. Connolly, Cynthia X. Ma, Antonio C. Wolff, Guillermo Villacampa, Thibault de La Motte Rouge, Joaquin G. Gregori
Proferred Paper/Oral Presentation #296O
Munich Auditorium - CityCube B | Friday, October 17, 2025 | 14:00-14:10 CEST (Oral) | 14:40-14:50 (Discussion)
Impact of Neoadjuvant Chemotherapy Response on Adjuvant Ribociclib Benefit in HR+/HER2− EBC: A NATALEE Analysis
Nicholas P. McAndrew, Stephen Chia, Fabio Puglisi, Yann Izarzugaza, Christian Schem, Binghe Xu, Fanny Le Du, Priyanka Sharma, Peter A. Fasching, Alejandro Rodriguez, Murat Akdere, Yogesh Chattar, Juan P. Zarate, Aditya Bardia
Poster Presentation #366P
Hall 25 | Monday, October 20, 2025 | 09:00-17:00 CEST (Poster)
A NATALEE Data-Based Machine Learning Model to Predict Distant Recurrence and Treatment Effect in Real-World Patients With HR+/HER2– Early Breast Cancer Without CDK4/6 Inhibitor Treatment
Frederick M. Howard, Peter A. Fasching, Cesar A. Santa-Maria, Elgene Lim, Joseph A. Sparano, Maryam B. Lustberg, Thomas Bachelot, Oleg Blyuss, Christine Brezden-Masley, Yeon H. Park, Murat Akdere, Fen Ye, Kristyn Pantoja, Patricia D. Castro, Christoph Kurz, Pedram Razavi
Poster Presentation #372P
Hall 25 | Monday, October 20, 2025 | 09:00-17:00 CEST (Poster)
Real-World Characteristics, Treatments and Outcomes of NATALEE and MonarchE-Eligible HR+/HER2– Early Breast Cancer Patients in the Hospital District of Helsinki and Uusimaa (HUS), Finland
Sari Voutilainen, Samuli Tuominen, Sari Hernesniemi, Mia Engström-Risku, Liisa Ukkola-Vuoti, Juhani Aakko, Björn Paulsson, Maija Wolf, Peeter Karihtala
Poster Presentation #360P
Hall 25 | Monday, October 20, 2025 | 09:00-17:00 CEST (Poster)
Real-World Evidence on Safety and Effectiveness Study of Ribociclib Plus Hormonal Therapy in HR+/HER2– Advanced Breast Cancer in the Middle East: Interim Results From the REALEESA Study
Hikmat Abdel-Razeq, Adher Alsayed, Emad Anwar, Suad Alkharusi, Syed H. Tirmazy, Ehab Saad, Leen Al Hawari, Mohamed Kasseb, Ola A. Hadi, Wesam Soliman
Poster Presentation #533P
Hall 25 | Monday, October 20, 2025 | 09:00-17:00 CEST (Poster)
Ribociclib Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2– Advanced or Metastatic Breast Cancer in Portugal: Final 3-Year Results From Breast Cancer Lighthouse Real-World Study
Leonor I. Pinto, Leonor Matos, Beatriz Gosalbez, Ângela Dias, Sofia Braga, António Pêgo, Catarina Abreu, Marta Ferreira, Patrícia Gago, Ilda Faustino, Idília Pina, Cristiana Marques, José L. Passos Coelho, Francisco Branco, Joana Simões, Inês Vaz-Luis, Fernando Schmitt, Luis Costa, Bárbara Rocha, Marco Domingues
Poster Presentation #531P
Hall 25 | Monday, October 20, 2025 | 09:00-17:00 CEST (Poster)
Real-World Characteristics, Treatment Patterns, and Outcomes in Patients With HR+/HER2− Early Breast Cancer From China and the US
Pedram Razavi, Qiao Li, Mingxia Jiang, Jiaxuan Liu, Mengqi Zhang, Hope S. Rugo, Joyce A. O'Shaughnessy, Erika Hamilton, Julia Kim, Murat Akdere, Baoling Sun, Vaidyanathan Ganapathy, Zuzanna Angehrn, Fen Ye, Binghe Xu
e-Poster Presentation #438eP
Saturday, October 18, 2025 (e-poster)
CAROLEEN: A Real-World Study Assessing Adjuvant Treatment Decision Dynamics and Outcomes in High-Risk HR+/HER2– eBC, Including Patient Compliance and Quality of Life
Bahriye Aktas, Thomas Decker, Sherko Kümmel, Maggie Banys-Paluchowski, Dominique Finas, Andreas Hartkopf, Wolfgang Janni, Michael P. Lux, Laura Michel, Marc Thill, Achim Wöckel, Rachel Würstlein, Thomas Resch, Claudia Karnthaler, Nicole Hannemann, Claudia Quiering, Christina Pfister
e-Poster Presentation #459eTiP
Saturday, October 18, 2025 (e-poster)
